Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.
| Revenue (TTM) | $591.33M |
| Gross Profit (TTM) | $350.12M |
| EBITDA | $22.91M |
| Operating Margin | 2.33% |
| Return on Equity | -236.40% |
| Return on Assets | -3.73% |
| Revenue/Share (TTM) | $6.48 |
| Book Value | $1.07 |
| Price-to-Book | 238.82 |
| Price-to-Sales (TTM) | 10.13 |
| EV/Revenue | 10.12 |
| EV/EBITDA | 1035.86 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 48.20% |
| Shares Outstanding | $94.26M |
| Float | $93.15M |
| % Insiders | 0.79% |
| % Institutions | 115.08% |
Volatility is currently expanding
Travere Therapeutics NASDAQ: TVTX is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and building its renal pipeline through the recently in-licensed BTK inhibitor civorebrutinib, Chief Financial Officer Chris Cline said at a Canaccord Genuity discussion.
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on August 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 12 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 38,940 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as.
Travere Therapeutics is downgraded from Buy to Hold after a >130% rally, reflecting competitive risks and valuation concerns. Filspari's Q2 net sales surged 96% YoY to $141M, but $3B+ peak sales guidance faces new competition in IgAN and FSGS markets. TVTX's pipeline expansion with civorebrutinib and pegtibatinase targets rare kidney and metabolic diseases, but both remain early-stage with uncertain timelines.
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity's 46th Annual Growth Conference Presenting on Tuesday, August 11, 2026, at 3:00 p.m. ET Wells Fargo 21st Annual Healthcare Conference Tuesday, September 8, 2026 Citi 2026 Biopharma Back to School Conference Wednesday, September 9, 2026 2026 Cantor Global Healthcare Conference Presenting on Thursday, Septe.
Travere Therapeutics NASDAQ: TVTX reported second-quarter results marked by record FILSPARI demand and revenue, driven by continued growth in IgA nephropathy and an early launch in focal segmental glomerulosclerosis, or FSGS.
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations.
NEW YORK, July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 shares of its common stock to six new employees, consisting of inducement stock options to purchase an aggregate of 18,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 23,600 shares of its common stock. These inducement s.
Travere Therapeutics has transitioned into a rare disease commercial platform, driven by FILSPARI's strong growth in IgAN and recent FSGS approval. TVTX's premium valuation is justified by rapid revenue expansion, significant operating leverage, and strategic pipeline moves like the civorebrutinib acquisition. FILSPARI's unique positioning and first-mover advantage in FSGS, alongside a simplified REMS, support continued market penetration despite a competitive IgAN landscape.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TVTX and any ticker you trade — then tracks every position and per-strategy win rate.
